抗癌治疗之间的时间表依赖的相互作用
Sheng-Hong Chen1, William Forrester2, Galit Lahav1
1Department of Systems Biology, Harvard Medical School, Boston, MA, USA.
概括
抑制瘤基因MDMX会重新激活瘤抑制剂p53,但其对癌细胞死亡的影响取决于p53.
科学领域:
- 癌症学
- 分子生物学
- 细胞信号传输
背景情况:
- 在许多癌症中,MDMX瘤基因过度表达,抑制瘤抑制剂p53.
- MDMX抑制剂可能会重新激活p53并增强破坏DNA的药物疗效.
- 缺乏对MDMX抑制对p53信号和DNA损伤敏感性的定量理解.
研究的目的:
- 量化研究MDMX抑制如何影响p53信号通路.
- 确定MDMX抑制对癌细胞对DNA损伤剂的敏感性的影响.
主要方法:
- 使用活细胞成像来观察MDMX耗尽后单细胞中的p53积累动态.
- 该研究分析了细胞在p53积累的不同阶段对DNA损伤的差异反应.
主要成果:
- MDMX耗尽导致p53积累的两个不同的阶段:最初的转移后脉冲和随后的低振幅振荡.
- 细胞对DNA损伤的反应在这些阶段之间有显著差异.
- 在第一阶段,MDMX枯竭与DNA损伤产生协同作用,导致细胞死亡.
- 在第二阶段,MDMX消耗抑制了DNA损伤引起的细胞死亡.
结论:
- 与DNA损伤相关的MDMX抑制时间对于治疗结果至关重要.
- 了解p53信号动态和细胞状态对于优化组合疗法至关重要.
- 这项研究为计划使用MDMX抑制剂和DNA破坏剂的双重药物提供了定量基础.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.6K
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11.6K
相关概念视频
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Therapies
10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Cancer Therapies
3.0K
3.0K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacokinetics: Drug–Drug Interactions
640
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
640
